A Single-Arm, Open-Label, Multi-Center Phase II Study to Evaluate the Combination of PVX-410 + Pembrolizumab + Chemotherapy for Frontline Therapy of Metastatic, PD-L1+ Triple-Negative Breast Cancer (TNBC) in HLA-A2-Positive Patients
Evaluating the combination of the investigational, multi-peptide cancer vaccine PVX-410 in combination with pembrolizumab and chemotherapy in treatment naive patients with metastatic, triple negative breast cancer who are PDL1 and HLA A2 positive.
100 项与 PD-L1阴性三阴性乳腺癌 相关的临床结果
100 项与 PD-L1阴性三阴性乳腺癌 相关的转化医学
0 项与 PD-L1阴性三阴性乳腺癌 相关的专利(医药)